Original versus generic drugs Review article

Main Article Content

Tomasz Drewa
Przemysław Adamczyk

Abstract

Retail of generic drugs is a common practice used extensively by the worldwide pharmaceutical industry. Generic drug manufacturer is not required to provide accurate preclinical or clinical studies to the registration authority, and it should determine drug bioavailability. Pharmacoeconomic benefits from the use of generic drugs are undeniable, and the differences in their chemical composition, as well as even slight modifications of active molecules, used by manufacturers of generic drugs, can be very important in their proper function. In the absence of trials comparing the original and generic drugs, it seems that the doctor is the only one to decide about patient’s treatment, because only he has adequate clinical experience and knows the possible side effects of the drug. In our opinion it is unacceptable for pharmaceutists to substitute drugs in arbitrary way. Unfortunately it is used sometimes in pharmacy practice.

Article Details

How to Cite
Drewa, T., & Adamczyk, P. (2014). Original versus generic drugs. Medycyna Faktow (J EBM), 7(4(25), 54-57. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2337
Section
Articles

References

1. Fugh-Berman A., Dodgson S.J.: Ethical considerations of publication planning in the pharmaceutical industry. Open Med. 2008; 2: 121-124.
2. Fugh-Berman A.: How basic scientists help the pharmaceutical industry market drugs. PLoS Biol. 2013; 11(11): e1001716.
3. Meredith P.: Drug safety 1996; 15: 233-242.
4. Hugh-Berman A.: How basic scientists help the pharmaceutical industry market drugs. PLoS Biol. 2013; 11: 11.
5. Payette M., Grant-Kels J.M.: Brand name versus generic drugs: the ethical quandary in caring for our sophisticated patients while trying to reduce health-care costs: facts and controversies. Clin. Dermatol. 2013; 31: 772-776.
6. Nickel J.C., Sander S., Moon T.D.: A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int. J. Clin. Pract. 2008; 62(10): 1547-1559.
7. Gellad W.F., Donohue J.M., Zhao X. et al.: Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison. Ann. Intern. Med. 2013; 16(159): 105-114.
8. Niho S., Yamanaka T., Umemura S. et al.: Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis. Jpn. J. Clin. Oncol. 2013; 43: 390-395.
9. Kwong W.J., Kamat S., Fang C.: Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients. Ann. Pharmacother. 2012; 46: 1609-1616.